PD-1/PD-L1 and DNA Damage Response in Cancer
The application of immunotherapy for cancer treatment is rapidly becoming more widespread. Immunotherapeutic agents are frequently combined with various types of treatments to obtain a more durable antitumor clinical response in patients who have developed resistance to monotherapy. Chemotherapeutic...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/12/4/530 |
| _version_ | 1827758203499184128 |
|---|---|
| author | Mateusz Kciuk Damian Kołat Żaneta Kałuzińska-Kołat Mateusz Gawrysiak Rafał Drozda Ismail Celik Renata Kontek |
| author_facet | Mateusz Kciuk Damian Kołat Żaneta Kałuzińska-Kołat Mateusz Gawrysiak Rafał Drozda Ismail Celik Renata Kontek |
| author_sort | Mateusz Kciuk |
| collection | DOAJ |
| description | The application of immunotherapy for cancer treatment is rapidly becoming more widespread. Immunotherapeutic agents are frequently combined with various types of treatments to obtain a more durable antitumor clinical response in patients who have developed resistance to monotherapy. Chemotherapeutic drugs that induce DNA damage and trigger DNA damage response (DDR) frequently induce an increase in the expression of the programmed death ligand-1 (PD-L1) that can be employed by cancer cells to avoid immune surveillance. PD-L1 exposed on cancer cells can in turn be targeted to re-establish the immune-reactive tumor microenvironment, which ultimately increases the tumor’s susceptibility to combined therapies. Here we review the recent advances in how the DDR regulates PD-L1 expression and point out the effect of etoposide, irinotecan, and platinum compounds on the anti-tumor immune response. |
| first_indexed | 2024-03-11T09:01:17Z |
| format | Article |
| id | doaj.art-cf20b859ebb94a98a6bc56be3d3de9f8 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-11T09:01:17Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-cf20b859ebb94a98a6bc56be3d3de9f82023-11-16T19:43:36ZengMDPI AGCells2073-44092023-02-0112453010.3390/cells12040530PD-1/PD-L1 and DNA Damage Response in CancerMateusz Kciuk0Damian Kołat1Żaneta Kałuzińska-Kołat2Mateusz Gawrysiak3Rafał Drozda4Ismail Celik5Renata Kontek6Department of Molecular Biotechnology and Genetics, University of Lodz, Banacha 12/16, 90-237 Lodz, PolandDepartment of Experimental Surgery, Faculty of Medicine, Medical University of Lodz, Narutowicza 60, 90-136 Lodz, PolandDepartment of Experimental Surgery, Faculty of Medicine, Medical University of Lodz, Narutowicza 60, 90-136 Lodz, PolandDepartment of Immunology and Allergy, Medical University of Lodz, Pomorska 251, 92-213 Lodz, PolandDepartment of Gastrointestinal Endoscopy, Wl. Bieganski Hospital, 91-347 Lodz, PolandDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Erciyes University, 38039 Kayseri, TurkeyDepartment of Molecular Biotechnology and Genetics, University of Lodz, Banacha 12/16, 90-237 Lodz, PolandThe application of immunotherapy for cancer treatment is rapidly becoming more widespread. Immunotherapeutic agents are frequently combined with various types of treatments to obtain a more durable antitumor clinical response in patients who have developed resistance to monotherapy. Chemotherapeutic drugs that induce DNA damage and trigger DNA damage response (DDR) frequently induce an increase in the expression of the programmed death ligand-1 (PD-L1) that can be employed by cancer cells to avoid immune surveillance. PD-L1 exposed on cancer cells can in turn be targeted to re-establish the immune-reactive tumor microenvironment, which ultimately increases the tumor’s susceptibility to combined therapies. Here we review the recent advances in how the DDR regulates PD-L1 expression and point out the effect of etoposide, irinotecan, and platinum compounds on the anti-tumor immune response.https://www.mdpi.com/2073-4409/12/4/530cytotoxic drugsDNA damage responseimmunotherapyprogrammed death ligand-1 (PD-L1) |
| spellingShingle | Mateusz Kciuk Damian Kołat Żaneta Kałuzińska-Kołat Mateusz Gawrysiak Rafał Drozda Ismail Celik Renata Kontek PD-1/PD-L1 and DNA Damage Response in Cancer Cells cytotoxic drugs DNA damage response immunotherapy programmed death ligand-1 (PD-L1) |
| title | PD-1/PD-L1 and DNA Damage Response in Cancer |
| title_full | PD-1/PD-L1 and DNA Damage Response in Cancer |
| title_fullStr | PD-1/PD-L1 and DNA Damage Response in Cancer |
| title_full_unstemmed | PD-1/PD-L1 and DNA Damage Response in Cancer |
| title_short | PD-1/PD-L1 and DNA Damage Response in Cancer |
| title_sort | pd 1 pd l1 and dna damage response in cancer |
| topic | cytotoxic drugs DNA damage response immunotherapy programmed death ligand-1 (PD-L1) |
| url | https://www.mdpi.com/2073-4409/12/4/530 |
| work_keys_str_mv | AT mateuszkciuk pd1pdl1anddnadamageresponseincancer AT damiankołat pd1pdl1anddnadamageresponseincancer AT zanetakałuzinskakołat pd1pdl1anddnadamageresponseincancer AT mateuszgawrysiak pd1pdl1anddnadamageresponseincancer AT rafałdrozda pd1pdl1anddnadamageresponseincancer AT ismailcelik pd1pdl1anddnadamageresponseincancer AT renatakontek pd1pdl1anddnadamageresponseincancer |